ondansetron has been researched along with Deafness in 1 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Deafness: A general term for the complete loss of the ability to hear from both ears.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Safaeian, R | 1 |
| Hassani, V | 1 |
| Asghari, A | 1 |
| Mohseni, M | 1 |
| Ashraf, H | 1 |
| Koleini, ZS | 1 |
1 trial available for ondansetron and Deafness
| Article | Year |
|---|---|
The effects of ondansetron versus dexamethasone on electrocardiographic markers of ventricular repolarization in children undergoing cochlear implant.
Topics: Antiemetics; Child; Cochlear Implantation; Cochlear Implants; Deafness; Dexamethasone; Double-Blind | 2020 |